CervoMed Inc. reports clinical-stage biotechnology developments centered on neflamapimod, an oral small-molecule drug candidate for age-related brain disorders. Company news most often covers dementia with Lewy bodies, the Phase 2b RewinD-LB trial, biomarker and MRI analyses, pharmacokinetic work, formulation and dosing disclosures, and regulatory interactions tied to later-stage development.
Updates also include financial results, grant revenue trends, investor conference presentations, shareholder voting matters, governance items, and capital-structure disclosures. CervoMed has also reported neflamapimod's inclusion in the UK EXPERTS-ALS platform for amyotrophic lateral sclerosis research.
CervoMed (NASDAQ: CRVO) reported initial Phase 2a results showing reduced mean levels of a neuronal-damage biomarker during neflamapimod treatment for nfvPPA.
In the trial’s open-label portion, mean plasma neurofilament light chain (NfL) declined by approximately 3.1 pg/mL over 12 weeks, mostly between weeks six and 12. An exploratory analysis of 13 participants with baseline NfL at or above the median showed an approximately 5.7 pg/mL decline. The trial enrolled 25 participants with nonfluent variant primary progressive aphasia, a form of dementia affecting speech. Glial fibrillary acidic protein (GFAP), another biomarker, remained stable.
Neflamapimod was generally well tolerated, with no new safety signals. One patient discontinued after elevated liver enzymes, which resolved after stopping treatment. CervoMed plans to present 24-week biomarker data in November 2026 and expects topline clinical data in the first quarter of 2027.
CervoMed (CRVO) reported results for a new 50 mg neflamapimod tablet and FDA removal of its prior drug-exposure limit.
In a Phase 1 study that met its primary objectives, a single tablet produced similar overall plasma exposure to the prior 40 mg capsule. Its peak concentration was approximately 20% lower, while its concentration 12 hours after dosing was approximately 20% higher. A controlled manufacturing process is designed to address variability seen with the earlier capsule. Following a 39-week dog study, the FDA removed the exposure limit that had constrained dosing.
CervoMed plans a 100 mg twice-daily regimen for future trials. Modeling projects approximately 33% higher trough concentration than the 40 mg three-times-daily regimen used in earlier dementia with Lewy bodies trials. The company said clinical data at 80 mg twice daily support the planned regimen’s safety and tolerability.
CervoMed (CRVO) will participate in the 5th Annual ROTH Healthcare Opportunities Conference in New York, NY, on Tuesday, September 29, 2026.
Company management is scheduled to join a panel titled “Frontiers in Neuroscience” from 10:00 AM to 10:50 AM ET and hold one-on-one meetings. The panel will not be webcast live, but a recording will be made available after the conference. Meeting requests and additional conference details can be obtained through a Roth institutional representative or by emailing cervomed@argotpartners.com.
CervoMed (CRVO)/b) will present initial biomarker results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) as a late-breaking oral session at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting in Philadelphia on October 11, 2026.The abstract acceptance was based on 12-week biomarker data from the trial’s first eight participants and the presentation will highlight initial 12-week results for two plasma biomarkers, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), from at least 22 study participants. The 25-patient Phase 2a trial, conducted at academic medical centers in the U.S. and U.K., is evaluating the safety, pharmacokinetics, and clinical effects of oral neflamapimod in nfvPPA, a type of frontotemporal dementia commonly associated with tau pathology that currently has no approved treatments in the U.S. or European Union.
The talk, titled “Initial Biomarker Results from a Phase 2a Clinical Trial of Neflamapimod in Patients with Nonfluent Variant Primary Progressive Aphasia (NCT07033481)”, is scheduled in Plenary 6 (Hot Topics) on Sunday, October 11, 2026, from 8:30 a.m. to 10:30 a.m. ET.
CervoMed (CRVO) will participate in two investor conferences in September 2026.
Management plans a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference on Friday, September 11, 2026, from 10:55 to 11:25 AM ET. The company will also give a presentation and hold 1x1 meetings at the H.C. Wainwright Global Investment Conference on Tuesday, September 15, 2026, from 4:00 to 4:30 PM ET, both with live webcasts available.
CervoMed (NASDAQ: CRVO) reported second quarter 2026 results and clinical progress for neflamapimod in dementia with Lewy bodies (DLB) and other indications. The company obtained a UK ILAP Innovation Passport for DLB, received a U.S. patent allowance extending DLB protection into 2042, and presented new RewinD-LB analyses at AAIC 2026 supporting a 50 mg TID dose and showing exposure- and biomarker‑linked CDR‑SB and MRI effects.
CervoMed completed enrollment in its Phase 2a nfvPPA trial and stopped enrollment in the RESTORE stroke trial. It raised about $20.5 million in June equity financings, ending June 30, 2026 with $24.9 million in cash and securities and runway through Q3 2027. Q2 R&D and G&A expenses declined year over year, while net loss was $6.6 million versus $6.3 million in 2025, mainly due to the absence of prior‑year grant revenue.
CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. Management plans to discuss recent progress in the neflamapimod clinical development program. The fireside chat is scheduled from 11:30–11:55 AM ET and will be available via webcast, including through the Investor section of the CervoMed website.
CervoMed (NASDAQ: CRVO) reported that its oral small-molecule candidate neflamapimod, which targets neuroinflammation in degenerative brain disorders, has been granted an Innovation Passport to enter the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB).
According to CervoMed, ILAP selection reflects joint consensus that neflamapimod is an innovative therapy addressing a high unmet need with potential major therapeutic advantage. The designation offers early, coordinated guidance and priority access to support from the MHRA, NHS, and UK health technology assessment bodies as the company prepares a planned Phase 3 DLB trial.
CervoMed (NASDAQ: CRVO) reported new clinical, plasma biomarker and MRI data for neflamapimod in dementia with Lewy bodies (DLB) at AAIC 2026. New analyses from the 159‑patient Phase 2b RewinD‑LB trial link treatment benefit to “pure” DLB patients with low plasma pTau181 and adequate drug exposure, and support a 50 mg three‑times‑daily dose for planned Phase 3 studies aligned with US and European regulators.
Neflamapimod was associated with durable slowing of right basal forebrain atrophy and increased basal forebrain connectivity versus placebo. A pharmacokinetic‑pharmacodynamic analysis identified a ~4 ng/mL plasma trough threshold tied to clinical and biomarker improvements. A separate 24‑week Phase 2 study in 26 patients showed an 80 mg twice‑daily dose met primary safety, tolerability and pharmacokinetic objectives, with encouraging but open‑label clinical activity signals.
CervoMed (NASDAQ: CRVO) completed enrollment in its Phase 2a study of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia.
The 25-patient trial assesses safety, pharmacokinetics and clinical effects, with interim biomarker data to be presented at CTAD 2026 and preclinical support published in Nature Neuroscience.